Clinically relevant quality assurance (QA) for prostate RapidArc plans: Gamma maps and DVH-based evaluation-Reference-Cited by-同舟云学术

Clinically relevant quality assurance (QA) for prostate RapidArc plans: Gamma maps and DVH-based evaluation

Published:2014-06 Issue:4 Volume:30 Page:462-472
ISSN:1120-1797
Container-title:Physica Medica
language:en
Short-container-title:Physica Medica

Author:

Cozzolino M.,Oliviero C.,Califano G.,Clemente S.,Pedicini P.,Caivano R.,Chiumento C.,Fiorentino A.,Fusco V.

Publisher

Elsevier BV

Subject

General Physics and Astronomy,Radiology Nuclear Medicine and imaging,General Medicine,Biophysics

Reference26 articles.

1. Volumetric modulated arc therapy: IMRT in a single gantry arc;Otto;Med Phys,2008

2. RapidArc volumetric modulated therapy planning for prostate cancer;Kjaer-Kristoffersen;Acta Oncol,2009

3. Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy;Palma;Int J Radiat Oncol Biol Phys,2008

4. Volumetric arc therapy (VMAT) reduces treatment time compared to conventional IMRT (cIMRT) while maintaining similar plan quality in whole pelvic gynecologic radiotherapy;Alexander;Int J Radiat Oncol Biol Phys,2008

5. Is IMAT the ultimate evolution of conformal radiotherapy? Dosimetric comparison of helical tomotherapy and volumetric modulated arc therapy for oropharyngeal cancer in a planning study;Servagi Vernat;Phys Med,2013

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of modulation factor and low dose threshold level on gamma pass rates of single isocenter multi‐target SRT treatment plans;Journal of Applied Clinical Medical Physics;2024-07-25

2. A structure-based gamma evaluation method for identifying clinically relevant dose differences in organs at risk;Physical and Engineering Sciences in Medicine;2023-05-23

3. A structure-based gamma evaluation method for identifying clinically relevant dose differences in organs at risk;2022-10-21

4. Optimizing the Region for Evaluation of Global Gamma Analysis for Nasopharyngeal Cancer (NPC) Pretreatment IMRT QA by COMPASS: A Retrospective Study;Frontiers in Oncology;2022-06-14

5. Implementation of TG‐218 for patient‐specific quality assurance tolerance and action limits determination: Gamma passing rate evaluation using 3DVH software;Medical Physics;2022-05-23